Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
YOLT-201 · 1 trial · 2 indications
Incidence and severity of adverse events (AEs) and serious adverse events (SAEs)
| Arm | Type | Description |
|---|---|---|
| YOLT-201 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| YOLT-201 | DRUG | Infusion of YOLT-201 at Day 1 |
Inclusion Criteria: 1. Age 18 - 80 years old (including the critical values), regardless of gender; 2. Body weight at the time of screening is between 40 - 90kg (including the critical values); 3. TTR gene mutation is confirmed by genetic testing; 4. At the time of screening, the following laborato...
YOLT-201 is an investigational small molecule being developed for the treatment of transthyretin amyloidosis polyneuropathy (ATTR-PN). It is also being studied in patients with transthyretin amyloidosis cardiomyopathy (ATTR-CM). The drug is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
YOLT-201 is being developed by cbdMD, Inc., a company traded on the stock market under the ticker YCBD. The company is conducting clinical trials of YOLT-201 in patients with transthyretin amyloidosis polyneuropathy and transthyretin amyloidosis cardiomyopathy.
YOLT-201 is in Phase 1 clinical development. It is currently being evaluated in an open-label, single ascending dose and dose-expansion study. The drug is investigational and has not received FDA approval or any other regulatory approval for commercial use.
YOLT-201 is being studied in a Phase I/IIa clinical trial with the identifier NCT06539208. This open-label, uncontrolled study is recruiting 31 participants in China to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of YOLT-201 in patients with transthyretin amyloidosis polyneuropathy or transthyretin amyloidosis cardiomyopathy.
No alternative names for YOLT-201 have been disclosed. The drug is identified solely by its code name YOLT-201 in clinical trial registrations and company communications. It is a distinct investigational compound being developed by cbdMD, Inc.